Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2022-09-30 00:00:00 ET · period of report 2022-09-29 · accession 0000899243-22-032297 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-09-30 | 2022-09-29 | KLRS | Hallal David | Dir, 10% | S - Sale | $7.35 | -400.0K | 721.0K | -36% | -$2.94M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-29 | S | D | 400,000 | $7.35 | 720,965 | I See Footnote | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.35 to $8.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. (F2) Shares held by The Hallal Family Irrevocable Trust 2012, for which the Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |